Table of Contents Table of Contents
Previous Page  291 / 812 Next Page
Information
Show Menu
Previous Page 291 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

S287

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.610

EW493

Medication and aggressiveness in

real-world schizophrenia. Results

from the FACE-SZ dataset

G. Fond

1 , M.

Favez

1 , L. B

oyer

2 , L. P

ierre-Michel

3 , A. P

elissol

o 1 ,

F. Berna

4 ,

1

Schizophrenia expert, center Fondation fondamental, Creteil, France

2

Pôle psychiatrie universitaire - CHU Sainte-Marguerite, pôle

psychiatrie universitaire, Marseille, France

3

Schizophrenia expert, center Fondation fondamental,

Clermont-Ferrand, France

4

Hôpitaux universitaires de Strasbourg- Inserm U1114- FMTS-

Fondation FondaMental, psychiatry, Strasbourg cedex, France

Corresponding author.

Introduction

The primary objective of this study was to deter-

mine if second generation antipsychotic (SGA) administration was

associated with lower aggressiveness scores compared to first gen-

eration (FGA) in schizophrenia (SZ). The secondary objective was

to determine if antidepressants, mood stabilizers and benzodi-

azepines administration were respectively associated with lower

aggressiveness scores compared to patients who were not admin-

istered these medications.

Methods

Three hundred and thirty-one patients with

schizophrenia (

n

= 255) or schizoaffective disorder (

n

= 76) (mean

age = 32.5 years, 75.5% male gender) were systematically included

in the network of FondaMental Expert Center for Schizophrenia

and assessed with the Structured Clinical Interview for DSM-IV

Axis I Disorders and validated scales for psychotic symptomato-

logy, insight and compliance. Aggressiveness was measured by

the Buss-Perry Aggression Questionnaire (BPAQ) score. Ongoing

psychotropic treatment was recorded.

Results

Patients who received SGA had lower BPAQ scores than

patients who did not (

P

= 0.01). On the contrary, patients who

received benzodiazepines had higher BPAQ scores than patients

who did not (

P

= 0.04). These results were found independently

of socio-demographical variables, psychotic symptomatology,

insight, compliance into treatment, daily-administered antipsy-

chotic dose, the way of antipsychotic administration (oral vs long

acting), current alcohol disorder and daily cannabis consumption.

Conclusion

The results of the present study are in favor of

the choice of SGA in SZ patients with aggressiveness, but these

results need further investigation in longitudinal studies. Given

the potent side effects of benzodiazepines (especially dependency

and cognitive impairment) and the results of the present study,

their long-term prescription is not recommended in patients with

schizophrenia and aggressive behavior.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.611

EW494

Emotional recognition during the

course of schizophrenia

D. Boˇsnjak

1 ,

, P. Makari´c

2

, M. Rojni´c Kuzman

3

1

University psychiatric hospital Vrapce, The Addictions Department,

Zagreb, Croatia

2

University psychiatric hospital Vrapce, The Department for

Diagnostics and Intensive Care, Zagreb, Croatia

3

Zagreb university hospital centre, department of psychiatry, Zagreb,

Croatia

Corresponding author.

Introduction

Adequate emotion identification ability facilitates

forming emotional relationships and effective communication.

Patients suffering from schizophrenia have deficits in emotional

recognition (ER), which leads to impaired social and occupational

functioning.

Objectives

To compare the differences in ER between the healthy

control group (HC) and two patient groups at different phases of

illness: first episode psychosis (FEP) and chronic, multi-episode

schizophrenia (MEP).

Aims

To investigate the pattern of emotional recognition deficit

during the course of schizophrenia.

Methods

We compared three groups of participants: MEP, FEP

and HC, each containing 50 participants, based on their emo-

tional recognition abilities using the Penn Emotion Recognition

Task and The I FEEL Pictures. Patients were diagnosed using Diag-

nostic and Statistical Manual of Mental Disorders, Fifth Edition

(DSM-5) criteria for schizophrenia (schizophreniform disorder)

with their psychopathology rated with the Positive and Negative

Syndrome Scale (PANSS) scale. Besides ER tasks, patients were

administered self-evaluation scales for the assessment of quality

of life, depression, suicidality, impulsivity, aggression, and relation-

ship with their parents.

Results

Our findings showed deficits in emotional recognition

ability of both patient groups in comparison with HC, especially

in the identification of negative emotions: sadness, fear and anger.

There was no statistically significant difference between groups in

the identification of happiness. First episode patients showed better

results than the MEP group.

Conclusions

Although the FEP group was more successful than

the ME group, our results showed that the emotional recognition

impairment exists at a significant level even at the beginning of the

illness.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.612

EW495

Medication adherence and cannabis

use among schizophrenic patients

S. Bouri

1 ,

, H. Zemmama

2

, K. El Ayoubi

2

, M.A. Berraho

3

,

A. Abdellaoui

4

, S. Achour

5

, I. Rammouz

2

1

Faculty of science- Dhar El Mahraz, laboratory physiology -

pharmacology & environmental health, Fez, Morocco

2

Faculty of medicine, clinical neurosciences laboratory, Fez, Morocco

3

Faculty of medicine, epidemiology public health, Fez, Morocco

4

Faculty of science, physiology- pharmacology-environmental

health, Fez, Morocco

5

University hospital Hassan II, toxicology unit, Fez, Morocco

Corresponding author.

Introduction

Substance use is usually associated with poorer

psychiatric medication adherence among schizophrenic patients.

Previous findings remain unclear about the relationship between

cannabis use and poor medication adherence. Identifying pre-

dictor factors of medication adherence among these patients

is very important because it’s associated with relapse and re-

hospitalization.

Objective

Determining whether cannabis use is a risk factor for

compliance tomedication in a populationof schizophrenic patients.

Method

Schizophrenic inpatients were assessed by Medication

Adherence Rating Scale (MARS). Socio-demographic, clinical data,

and urine drug screens were collected just after their admission.

Results

A sample of 403 inpatientswith schizophrenia diagnosed

withDiagnostic and Statistical Manual of Mental Disorders, 4th Edi-

tion (DSM-IV) criteria (mean age = 33, 35

±

9, 16), predominantly

man (90%), paranoid (62%) and 89% of them received classical

antipsychotics. A total of (

n

= 25; 6, 2%) inpatients were adher-

ent, among this group, 19 patients (76%) were tested negative for